Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 2.85
SPHS's Cash to Debt is ranked higher than
51% of the 702 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.66 vs. SPHS: 2.85 )
Ranked among companies with meaningful Cash to Debt only.
SPHS' s 10-Year Cash to Debt Range
Min: 0.39  Med: 765.60 Max: No Debt
Current: 2.85
F-Score: 3
Z-Score: -11.03
M-Score: -3.30
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
ROE (%) -126.14
SPHS's ROE (%) is ranked lower than
97% of the 685 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.31 vs. SPHS: -126.14 )
Ranked among companies with meaningful ROE (%) only.
SPHS' s 10-Year ROE (%) Range
Min: -2308.71  Med: -85.21 Max: -8.7
Current: -126.14
-2308.71
-8.7
ROA (%) -82.71
SPHS's ROA (%) is ranked lower than
96% of the 706 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.19 vs. SPHS: -82.71 )
Ranked among companies with meaningful ROA (%) only.
SPHS' s 10-Year ROA (%) Range
Min: -157.85  Med: -73.33 Max: -8.51
Current: -82.71
-157.85
-8.51
ROC (Joel Greenblatt) (%) -63387.25
SPHS's ROC (Joel Greenblatt) (%) is ranked lower than
99% of the 704 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 12.13 vs. SPHS: -63387.25 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
SPHS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -52607.02  Med: -7751.87 Max: -2275.11
Current: -63387.25
-52607.02
-2275.11
EBITDA Growth (3Y)(%) -31.20
SPHS's EBITDA Growth (3Y)(%) is ranked lower than
88% of the 483 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.80 vs. SPHS: -31.20 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
SPHS' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -31.2  Med: -5.30 Max: 72.9
Current: -31.2
-31.2
72.9
EPS Growth (3Y)(%) -32.70
SPHS's EPS Growth (3Y)(%) is ranked lower than
84% of the 452 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.20 vs. SPHS: -32.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
SPHS' s 10-Year EPS Growth (3Y)(%) Range
Min: -32.7  Med: -4.10 Max: 70.5
Current: -32.7
-32.7
70.5
» SPHS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

SPHS Guru Trades in Q1 2014

First Eagle Investment 250,000 sh (unchged)
» More
Q2 2014

SPHS Guru Trades in Q2 2014

First Eagle Investment 250,000 sh (unchged)
» More
Q3 2014

SPHS Guru Trades in Q3 2014

First Eagle Investment 250,000 sh (unchged)
» More
Q4 2014

SPHS Guru Trades in Q4 2014

First Eagle Investment Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with SPHS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.32
SPHS's P/B is ranked higher than
81% of the 665 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.42 vs. SPHS: 1.32 )
Ranked among companies with meaningful P/B only.
SPHS' s 10-Year P/B Range
Min: 0.18  Med: 1.14 Max: 8.66
Current: 1.32
0.18
8.66
EV-to-EBIT -0.11
SPHS's EV-to-EBIT is ranked lower than
180% of the 489 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 26.18 vs. SPHS: -0.11 )
Ranked among companies with meaningful EV-to-EBIT only.
SPHS' s 10-Year EV-to-EBIT Range
Min: -11.5  Med: -0.50 Max: 3.5
Current: -0.11
-11.5
3.5
Current Ratio 4.82
SPHS's Current Ratio is ranked higher than
77% of the 607 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.27 vs. SPHS: 4.82 )
Ranked among companies with meaningful Current Ratio only.
SPHS' s 10-Year Current Ratio Range
Min: 0.6  Med: 5.71 Max: 118.33
Current: 4.82
0.6
118.33
Quick Ratio 4.82
SPHS's Quick Ratio is ranked higher than
80% of the 606 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.66 vs. SPHS: 4.82 )
Ranked among companies with meaningful Quick Ratio only.
SPHS' s 10-Year Quick Ratio Range
Min: 0.6  Med: 5.71 Max: 118.33
Current: 4.82
0.6
118.33

Valuation & Return

vs
industry
vs
history
Price/Net Cash 1.75
SPHS's Price/Net Cash is ranked higher than
94% of the 171 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.52 vs. SPHS: 1.75 )
Ranked among companies with meaningful Price/Net Cash only.
SPHS' s 10-Year Price/Net Cash Range
Min: 0.77  Med: 1.79 Max: 14.62
Current: 1.75
0.77
14.62
Price/Net Current Asset Value 1.33
SPHS's Price/Net Current Asset Value is ranked higher than
96% of the 361 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.04 vs. SPHS: 1.33 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
SPHS' s 10-Year Price/Net Current Asset Value Range
Min: 0.62  Med: 1.62 Max: 9.93
Current: 1.33
0.62
9.93
Price/Tangible Book 1.33
SPHS's Price/Tangible Book is ranked higher than
83% of the 614 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.15 vs. SPHS: 1.33 )
Ranked among companies with meaningful Price/Tangible Book only.
SPHS' s 10-Year Price/Tangible Book Range
Min: 0.62  Med: 1.62 Max: 9.88
Current: 1.33
0.62
9.88
Earnings Yield (Greenblatt) (%) -908.16
SPHS's Earnings Yield (Greenblatt) (%) is ranked lower than
100% of the 689 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.30 vs. SPHS: -908.16 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
SPHS' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -965.65  Med: 36.10 Max: 974.9
Current: -908.16
-965.65
974.9

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare: » details
Traded in other countries:SHS.Canada, BFF1.Germany,
Sophiris Bio Inc was formed in May 2003 under the predecessor to the Business Corporations Act by the amalgamation of Stratos Biotechnologies Inc., Nucleus BioScience Inc. and Brightwave Ventures Inc. It began operations on January 11, 2002. The Company's operations were initially located in Vancouver, British Columbia. Effective April 2, 2012, the Company changed its name from Protox Therapeutics Inc. to Sophiris Bio Inc. The Company is a clinical-stage biopharmaceutical company that develops and commercializes innovative products for the treatment of urological diseases. It is currently developing PRX302 for treatment of the symptoms of benign prostatic hyperplasia. BPH is a non-cancerous enlargement of the prostate gland that commonly affects men who are age 50 and older. The Company expects that PRX302 will compete with the current treatment options for the symptoms of BPH, which include oral drug therapy and surgery. Its business and operations are subject to a variety of U.S. federal, state and local, and foreign supranational, national, provincial and municipal laws, regulations and trade practices. As of December 31, 2012, it had nine full-time employees and one part-time employee.
» More Articles for NAS:SPHS

Headlines

Articles On GuruFocus.com
Weekly 3-Year Low Highlights: STRA, IMI, HXM, SPHS Jan 06 2014 
From The Land of What If - Smart Proteins and Debt Collectors Sep 28 2013 
Sleepy Sector Wakes Up - Billionaires Hold Biotechs in 52-week Low Sep 03 2013 

More From Other Websites
Sophiris Bio to Present at the LD Micro Invitational Conference May 27 2015
Sophiris Bio Enrolls First Patients in Phase 2a Proof of Concept Prostate Cancer Study May 26 2015
Sophiris Bio Reports First Quarter Financial Results May 13 2015
Sophiris Bio to Present at the Needham Healthcare Conference Apr 02 2015
Sophiris Bio Reports Fourth Quarter and Full Year Financial Results Mar 10 2015
Sophiris Bio to Present at the Leerink Global Healthcare Conference Jan 29 2015
Sophiris Bio's Lead Drug Study Looks Unpromising Dec 15 2014
Sophiris Bio Reports Administrative Interim Analysis for the "PLUS-1" Phase 3 Trial of PRX302 for... Dec 15 2014
Sophiris Bio to Present at the 26th Annual Piper Jaffray Healthcare Conference Nov 25 2014
Sophiris Bio Reports Third Quarter Financial Results Nov 12 2014
Sophiris Bio to Present at the Stifel 2014 Healthcare Conference Nov 07 2014
Strength Seen in Sophiris Bio (SPHS): Stock Soars 25% Nov 05 2014
Sophiris Bio to Present at the 13th Annual BIO Investor Forum Sep 30 2014
Sophiris Bio Reports Completion of Enrollment in the "PLUS-1" Phase 3 Trial of PRX302 for Benign... Sep 02 2014
Sophiris Bio Reports Second Quarter Financial Results and Key Operational and Financial Highlights Aug 07 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK